The operating profit of the JLR surged 5.12 percentage points on a YoY basis to 8.8% in December quarter, taking the nine-month margin to 8.2%, driven by increasing volume that helped it accrue benefits of operating leverage, better product mix and tailwinds of moderating raw material prices.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the